Nectar Lifescience Peer Comparison
NSE: NECLIFE | BSE: 532649
₹9.81
As on 20-Nov-2026IST
Market cap
₹192 Cr
Revenue (TTM)
₹2 Cr
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
192 | 44,317 | 26,472 | 17,792 | 13,467 |
Revenue (₹ Cr) |
2 | 10,234 | 2,307 | 2,684 | 710 |
Net Profit (₹ Cr) |
-66.33 | 1,092.67 | 452.55 | 669.74 | 188.64 |
Net Margin (%) |
71.12 | 10.67 | 19.31 | 24.24 | 25.69 |
RoE (%) |
-0.69 | 21.65 | 23.18 | 19.79 | 20.46 |
Price to Earnings |
-- | 40.53 | 58.50 | 26.57 | 71.50 |
Price-To-Book |
0.34 | 8.29 | 13.05 | 4.90 | 14.07 |
Income Statement (₹ Cr)
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1.74 | 10,234.10 | 2,307.19 | 2,684.41 | 709.64 |
|
Total Income
|
25.67 | 10,245.27 | 2,343.69 | 2,763.43 | 734.34 |
|
Total Expenditure
|
94.85 | 8,141.47 | 1,602.28 | 1,761.70 | 458.93 |
|
EBITDA
|
-93.11 | 2,092.63 | 704.92 | 922.70 | 250.72 |
|
Depreciation
|
0.37 | 430.12 | 104.34 | 82.27 | 17.12 |
|
EBIT
|
-93.48 | 1,662.51 | 600.57 | 840.44 | 233.59 |
|
Interest
|
36.28 | 151.49 | 28.27 | 5.42 | 8.49 |
|
Other Income
|
23.93 | 11.17 | 36.50 | 79.02 | 24.69 |
|
Exceptional Items
|
88.15 | -27.85 | 0.00 | -25.66 | 0.00 |
|
Profit before Tax
|
-17.68 | 1,494.35 | 608.80 | 888.39 | 249.79 |
|
Provision for Tax
|
-35.93 | 401.68 | 156.25 | 218.65 | 61.16 |
|
Profit after Tax
|
18.26 | 1,092.67 | 452.55 | 669.74 | 188.64 |
Liabilities (₹ Cr)
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
569.62 | 5,344.04 | 2,029.71 | 3,631.29 | 957.32 |
|
Minority Interest
|
0.00 | 0.82 | 0.00 | 0.00 | -0.30 |
|
Non-Current Liabilities
|
11.50 | 980.81 | 381.27 | 146.95 | 106.92 |
|
Current Liabilities
|
20.21 | 3,838.93 | 618.58 | 563.70 | 248.88 |
|
Total Liabilities
|
621.61 | 9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 |
Assets (₹ Cr)
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
334.88 | 3,542.74 | 1,471.67 | 1,454.42 | 534.87 |
|
Current Assets
|
235.30 | 6,027.59 | 1,389.85 | 2,864.85 | 723.33 |
|
Total Assets
|
621.61 | 9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 |
|
Total Debt*
|
0.00 | 1,204.08 | 196.61 | 0.00 | 148.29 |
|
Net Current Assets
|
215.08 | 2,188.66 | 771.28 | 2,301.15 | 474.44 |
|
Contingent Liabilities
|
229.52 | 258.92 | 13.18 | 4.82 | -- |
Cashflow (₹ Cr)
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-348.72 | 943.55 | 346.68 | 565.41 | 69.55 |
|
Cash Flow from Investing Activities
|
1,208.15 | -1,193.06 | -423.73 | -570.15 | -330.93 |
|
Cash from Financing Activities
|
-766.51 | 343.43 | 20.98 | -64.34 | 247.29 |
|
Net Cash Inflow / Outflow
|
92.91 | 93.92 | -56.08 | -69.08 | -14.09 |
Ratios
Profitability Ratios
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-4.75 | 25.25 | 27.50 | 24.61 | 28.50 |
|
ROE (%)
|
-0.69 | 21.65 | 23.18 | 19.79 | 20.46 |
|
ROA (%)
|
1.51 | 11.17 | 16.27 | 16.78 | 16.29 |
|
EBIT Margin (%)
|
-5,362.88 | 16.24 | 26.03 | 31.31 | 32.92 |
|
Net Margin (%)
|
71.12 | 10.67 | 19.31 | 24.24 | 25.69 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
138.11 | 21.12 | 50.46 | 8.19 | 26.57 |
|
EBIT Growth (%)
|
-51,259.89 | 32.84 | 138.53 | 24.77 | 26.37 |
|
Net Profit Growth (%)
|
3,451.75 | 33.33 | 88.45 | 26.27 | 24.97 |
|
EPS Growth (%)
|
-2,355.47 | 38.63 | 131.13 | 29.79 | 8.48 |
|
Book Value Growth (%)
|
-39.10 | 11.36 | 22.95 | 18.43 | 79.97 |
Valuation Ratios
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-19.21 | 39.78 | 58.29 | 25.77 | 71.37 |
|
Price / Book Value
|
0.34 | 8.30 | 13.00 | 4.90 | 14.04 |
|
Dividend Yield (%)
|
0.00 | 0.15 | 0.17 | 0.35 | 0.13 |
|
EV/EBITDA
|
-0.73 | 21.69 | 37.20 | 18.43 | 53.74 |
|
Market Cap (₹ Cr)
|
-- | 30,257.56 | 15,412.11 | 11,956.86 | 6,690.53 |
Solvency Ratios
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.10 | 0.10 | 0.00 | 0.07 |
|
Short term debt to equity ratio
|
-- | 0.16 | -- | -- | 0.12 |
|
Current Ratio
|
11.64 | 1.57 | 2.25 | 5.08 | 2.91 |
|
Quick Ratio
|
11.64 | 0.92 | 1.35 | 3.69 | 1.80 |
|
Interest Coverage
|
0.51 | 10.86 | 22.53 | 165.03 | 30.42 |
Operating Efficiency Ratios
| Nectar Lifescience | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 26.69 | 12.76 | 36.81 | 34.68 |
|
Asset Turnover
|
0.00 | 1.05 | 0.83 | 0.67 | 0.61 |
|
Receivable days
|
-- | 88.68 | 77.32 | 144.58 | 115.16 |
|
Inventory Days
|
-- | 84.11 | 80.83 | 96.67 | 96.15 |
|
Payable days
|
-- | 176.65 | 125.94 | 135.45 | 106.08 |
|
Cash Conversion Cycle
|
-- | -3.86 | 32.22 | 105.80 | 105.23 |